A Radioactive Peptide Beat Standard Care in a Rare Cancer Trial

Bristol Myers Squibb says a radioactive peptide has, for the first time, won a Phase 3 trial outright against the treatments doctors already reach for once a rare tumor stops responding — not against a placebo.

The company announced on October 12, 2026, that RYZ101, an investigational therapy from its subsidiary RayzeBio, met the primary endpoint of the Phase 3 ACTION-1 trial at a planned interim analysis: a statistically significant, clinically meaningful improvement in progression-free survival, measured by reviewers blinded to which arm each patient was on. RayzeBio's chief medical officer, Amreen Husain, called it "a defining moment for RYZ101." Principal investigator Simron Singh, MD, of Sunnybrook Health Sciences Centre, said the result is the first Phase 3 evidence anywhere for an alpha-particle-based targeted radiopharmaceutical, according to OncLive's coverage of the announcement.

A peptide built to carry a radioactive warhead

RYZ101 is two pieces bolted together. The first is DOTATATE, a synthetic peptide engineered to resemble somatostatin, a hormone the body makes, closely enough to bind tightly to somatostatin receptors on cell surfaces. The second is actinium-225, a radioactive isotope that decays by emitting alpha particles.

Most gastroenteropancreatic neuroendocrine tumors (GEP-NETs) carry unusually high numbers of one somatostatin receptor subtype, expressed on 80% to 90% of these tumors, Bristol Myers Squibb said in its announcement. The DOTATATE half of the molecule seeks out those receptors and drags the radioactive half along with it, concentrating radiation inside the tumor rather than spreading it through the body.

The already-approved version of this idea, Novartis's lutetium-177 dotatate (sold as Lutathera), uses the same DOTATATE peptide but pairs it with a beta-emitting isotope instead of an alpha emitter. That swap matters more than it sounds. A peer-reviewed comparison of lutetium-177 and actinium-225 radioligands reports that beta particles travel roughly 1.5 to 1.7 millimeters through tissue and damage DNA mostly indirectly, through free radicals, while alpha particles travel only about 50 to 80 micrometers — a few cell widths — but tend to carve direct, hard-to-repair breaks in both strands of the DNA helix. The same review notes a study in which an alpha-emitting prostate-targeting drug produced a comparable amount of DNA damage using only about 1% of the radioactive activity of its beta-emitting counterpart.

What the trial showed, and the numbers it didn't

ACTION-1 enrolled adults with somatostatin-receptor-positive GEP-NETs whose tumors had already progressed after lutetium-177 therapy — patients who, under current practice, had already used up the one targeted radioactive option available to them. The trial randomized participants to RYZ101 or to the investigator's choice of standard care: high-dose or high-frequency somatostatin analogues, everolimus, or sunitinib.

What Bristol Myers Squibb has disclosed, as of this interim look, is that RYZ101 beat that standard-of-care arm on progression-free survival, by a margin the company calls both statistically significant and clinically meaningful. What it has not disclosed is almost everything a clinician would want next: the median progression-free survival in either arm, the hazard ratio, the number of progression events counted, or safety data beyond "consistent with the known safety profile." Overall survival, the trial's longer-term question, is still being followed and was not reported.

That gap is ordinary practice — companies routinely post topline results ahead of the medical meeting where the full data package appears — but it means this announcement describes a direction, not a magnitude. An earlier, far smaller phase 1b study of 17 previously treated patients found no treatment-related serious adverse events and no discontinuations for side effects, which is reassuring but far too small a sample to establish a safety profile on its own.

Why alpha emitters are the field's next step

Lutathera's 2018 approval, built on the Phase 3 NETTER-1 trial, made this kind of peptide-guided radiotherapy a standard tool against GEP-NETs, but it didn't make it a cure: most patients eventually progress even on lutetium-177, which is exactly the population ACTION-1 recruited from. Until now, there was no randomized trial evidence for what to offer a patient whose tumor has already outlasted a beta-emitting radioligand.

If ACTION-1's interim read holds up once the full data are public, it would be the first demonstration that switching a patient to an alpha-emitting version of essentially the same homing peptide can still produce a measurable benefit — treating the isotope, not the peptide, as the variable worth re-engineering. RayzeBio's broader pipeline, per the company, includes other alpha-conjugated peptides aimed at different receptor targets, so this reads less like a single drug bet than a test of the whole approach.

It's also, for a drug class built around a hormone most people have never heard of, a reminder that swapping one radioactive atom for another, on an otherwise unchanged peptide, can be enough to turn a years-old approved therapy into a defining-moment press release.

What this means for researchers

ACTION-1's interim result is a real signal: an independent, blinded review found a statistically significant difference, in a randomized trial, in a population with no approved next-line option. That's a meaningfully higher bar of evidence than most peptide research clears, where single-arm or animal studies are still the norm. It's worth setting alongside an earlier case covered in this journal, where a slower-acting cancer peptide improved outcomes in mice by changing its release timing rather than its target — another reminder that in oncology peptide programs, how and when a molecule acts can matter as much as what it's aimed at.

What isn't yet known should temper any reaction to the headline: the actual size of the progression-free survival benefit, whether it translates into longer survival, and the full safety picture are all still pending presentation at a future medical meeting. The FDA's orphan drug designation, granted to RYZ101 in August 2026, lowers some procedural barriers but is not a review of efficacy or safety, and RayzeBio has not said when it expects to file for approval.

For researchers following peptide-drug conjugate science, ACTION-1 is a useful marker of where the field's hardest evidence — randomized, blinded, Phase 3 — is actually being generated right now: not in metabolic peptides, but in oncology, where a decades-old hormone-mimicking peptide is being re-engineered one isotope at a time.